A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)

Study summary

This is a multi-center observational study in subjects with a diagnosis of small cell lung cancer. Screening and/or medical record review for symptoms associated with Lambert Eaton Myasthenic Syndrome (LEMS) will be conducted.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forSmall cell lung cancer (SCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 4, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Withdrawn

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Addario Lung Cancer Medical Institute

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Addario Lung Cancer Medical Institute
Interventions being studied: Not specified

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Small cell lung cancer (SCLC)→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. Adult men or women meeting Age of Majority (AOM) at the time of consent 2. Provide voluntary consent to participate in this study, documented via a signed informed Consent Form (ICF) 3. Any diagnosis of SCLC 4. Willing to provide clinical and medical information related to his/her cancer diagnoses to the study team as required 5. Willing to comply with the requirements of the study

Reasons someone may not be able to joinExclusion criteria

1. Has been diagnosed with non-tumor Lamber-Eaton Myasthenic syndrome (LEMS) \> 1 year prior to the SCLC diagnosis. 2. Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Dana-Farber Cancer InstituteBoston, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 4, 2026. Always confirm current availability with the study team.

View original record ↗